Black Diamond Therapeutics (BDTX) Cash from Operations (2019 - 2026)
Black Diamond Therapeutics (BDTX) posted Cash from Operations of 10232000.0 for Q1 2026, down 50.76% on a QoQ basis from 6787000.0 in Q4 2025, and down 119.16% year-over-year from 53410000.0 in Q1 2025.
Black Diamond Therapeutics (BDTX) Cash from Operations (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 10232000.0 for Q1 2026.
- Quarterly Cash from Operations fell 119.16% year-over-year to 10232000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34028000.0 (down 376.52% YoY) and the FY2025 annual result came in at 29614000.0, up 147.53% from the prior year.
- Cash from Operations was 10232000.0 for Q1 2026 at Black Diamond Therapeutics, down from 6787000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 53410000.0 in Q1 2025 and bottomed at 28600000.0 in Q1 2022.
- A 5-year average of 11454117.65 and a median of 14726000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2025 — Cash from Operations jumped 351.95% — and 2026, when it plunged 119.16%.
- Black Diamond Therapeutics' Cash from Operations stood at 21939000.0 in 2022, then surged by 36.39% to 13956000.0 in 2023, then slipped by 7.87% to 15055000.0 in 2024, then surged by 54.92% to 6787000.0 in 2025, then sank by 50.76% to 10232000.0 in 2026.
- Business Quant data shows BDTX's Cash from Operations at 10232000.0 in Q1 2026, 6787000.0 in Q4 2025, and 7850000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | -10.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.23 Mn |
| Mar 31, 2026 | -10.23 Mn |
| Dec 31, 2025 | -6.79 Mn |
| Dec 31, 2025 | -6.79 Mn |
| Sep 30, 2025 | -7.85 Mn |
| Sep 30, 2025 | -7.85 Mn |
| Jun 30, 2025 | -9.16 Mn |
| Jun 30, 2025 | -9.16 Mn |
| Mar 31, 2025 | 53.41 Mn |
| Mar 31, 2025 | 53.41 Mn |
| Dec 31, 2024 | -15.06 Mn |
| Dec 31, 2024 | -15.06 Mn |
| Sep 30, 2024 | -11.32 Mn |
| Sep 30, 2024 | -11.32 Mn |
| Jun 30, 2024 | -14.73 Mn |
| Jun 30, 2024 | -14.73 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Dec 31, 2023 | -13.96 Mn |
| Dec 31, 2023 | -13.96 Mn |